Ashland logo

Ashland

ASH | NYSE
Chart Builder DCF Calculator
$75.57
-$0.90 (-1.18%)
At close: Nov 16, 2026, 4:00 PM ET
$74.50
-$1.07 (-1.42%)
After-hours: Nov 16, 2026, 4:39 PM ET
-1.18%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
36.3
Fundamentals Weak
Market Sentiment Bullish
Moat Narrow
Sector Rank #274/394 (Top 70%)

Key Statistics

Market Data

Market Cap $3.46B
1D Range
75.16 76.52
52W Range
48.18 77.70

Valuation (TTM)

PE 139.94
PB 1.87
EV/EBITDA 15.96

Valuation (NTM)

Forward PE 18.08
Forward PEG 40.61
Price Target $78.00
Loading financial charts...

Profile

Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty ...

Employees 2,900
IPO Date Mar 17, 1980
Fiscal Year October - September

Latest News

Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models

17 hours ago · businesswire.com

Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
Ashland: Focus On FY 2027 Financial Improvement And Potential Sale

3 days ago · seekingalpha.com

Ashland: Focus On FY 2027 Financial Improvement And Potential Sale
Ashland board authorizes quarterly dividend

5 days ago · globenewswire.com

Ashland board authorizes quarterly dividend
ASH Q4 Earnings Miss Estimates Despite Strong Segment Growth

6 days ago · zacks.com

ASH Q4 Earnings Miss Estimates Despite Strong Segment Growth
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

12 days ago · globenewswire.com

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
What Ashland (ASH) Said on Its Q4 Earnings Call

12 days ago · marketbeat.com

What Ashland (ASH) Said on Its Q4 Earnings Call
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting

13 days ago · globenewswire.com

Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026

13 days ago · globenewswire.com

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

13 days ago · businesswire.com

Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease

13 days ago · prnewswire.com

Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease

Earnings

Latest Earnings
Nov 3, 2026
EPS
$1.12
Miss -11.81%
REV
$498M
Miss -0.75%
Next Earnings
Feb 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$78.00
Upside
+3.22%
Buy (6)
Hold (3)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.